Article Text

Download PDFPDF
Randomised controlled trial
Percutaneous coronary intervention for acute coronary syndrome: no difference in 48-h bleeding rate or vascular access-site complications with low- or standard-dose unfractionated heparin in patients initially treated with fondaparinux

Statistics from


  • Competing interests AML has received research funding and consulting honoraria from Roche, Bristol-Myers Squibb and Schering Plough. AK has no disclosures to report.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.